IDENIX PHARM
Norcod AS engages in the farming, production, operation, distribution, marketing, and sale of farmed cod products in Norway and internationally. The company was incorporated in 2018 and is headquartered in Trondheim, Norway.
IDENIX PHARM (NO9) - Net Assets
Latest net assets as of September 2025: €139.91 Million EUR
Based on the latest financial reports, IDENIX PHARM (NO9) has net assets worth €139.91 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€588.63 Million) and total liabilities (€448.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €139.91 Million |
| % of Total Assets | 23.77% |
| Annual Growth Rate | 39.09% |
| 5-Year Change | -59.78% |
| 10-Year Change | N/A |
| Growth Volatility | 485.27 |
IDENIX PHARM - Net Assets Trend (2019–2024)
This chart illustrates how IDENIX PHARM's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IDENIX PHARM (2019–2024)
The table below shows the annual net assets of IDENIX PHARM from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | €156.09 Million | -30.57% |
| 2023-09-30 | €224.81 Million | +27.24% |
| 2022-09-30 | €176.68 Million | -42.87% |
| 2021-09-30 | €309.24 Million | -20.32% |
| 2020-09-30 | €388.10 Million | +1195.10% |
| 2019-09-30 | €29.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to IDENIX PHARM's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 85457300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.02 Billion | 655.60% |
| Total Equity | €156.09 Million | 100.00% |
IDENIX PHARM Competitors by Market Cap
The table below lists competitors of IDENIX PHARM ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sino Horizon Holdings Ltd
TW:2923
|
$24.68 Million |
|
SRG Mining Inc
PINK:SRGMF
|
$24.69 Million |
|
Wafangdian Bearing Co Ltd
SHE:200706
|
$24.70 Million |
|
Proteomics International Laboratories Ltd
AU:PIQ
|
$24.70 Million |
|
Alves Kablo San As
IS:ALVES
|
$24.66 Million |
|
Southern Acids (M) Bhd
KLSE:5134
|
$24.66 Million |
|
Astro Malaysia Holdings Bhd
KLSE:6399
|
$24.66 Million |
|
Korea Ind
KO:002140
|
$24.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IDENIX PHARM's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 224,807,000 to 156,092,000, a change of -68,715,000 (-30.6%).
- Net loss of 235,003,000 reduced equity.
- New share issuances of 166,289,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-235.00 Million | -150.55% |
| Share Issuances | €166.29 Million | +106.53% |
| Other Changes | €-1.00K | -0.0% |
| Total Change | €- | -30.57% |
Book Value vs Market Value Analysis
This analysis compares IDENIX PHARM's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.24x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.52x to 0.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-09-30 | €1.66 | €0.87 | x |
| 2020-09-30 | €21.53 | €0.87 | x |
| 2021-09-30 | €17.48 | €0.87 | x |
| 2022-09-30 | €8.87 | €0.87 | x |
| 2023-09-30 | €7.51 | €0.87 | x |
| 2024-09-30 | €3.57 | €0.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IDENIX PHARM utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -150.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -59.17%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 4.32x
- Recent ROE (-150.55%) is below the historical average (-80.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -32.52% | -173.73% | 0.15x | 1.22x | €-12.74 Million |
| 2020 | 1.46% | 78.49% | 0.02x | 1.20x | €-33.14 Million |
| 2021 | -24.30% | -103.47% | 0.13x | 1.80x | €-106.08 Million |
| 2022 | -168.22% | -174.28% | 0.31x | 3.07x | €-314.88 Million |
| 2023 | -109.51% | -91.37% | 0.39x | 3.09x | €-268.66 Million |
| 2024 | -150.55% | -59.17% | 0.59x | 4.32x | €-250.61 Million |
Industry Comparison
This section compares IDENIX PHARM's net assets metrics with peer companies in the Farm Products industry.
Industry Context
- Industry: Farm Products
- Average net assets among peers: $3,551,619,056,885
- Average return on equity (ROE) among peers: -12.62%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IDENIX PHARM (NO9) | €139.91 Million | -32.52% | 3.21x | $24.66 Million |
| China Modern Dairy Holdings Ltd (07M) | $7.12 Billion | -10.42% | 1.50x | $503.81 Million |
| PT Charoen Pokphand Indonesia Tbk (0CP1) | $27.03 Trillion | 8.58% | 0.52x | $1.29 Billion |
| Bumitama Agri Ltd (2BU) | $8.47 Trillion | 14.09% | 0.80x | $282.39 Million |
| Green Rise Foods Inc. (6VN) | $3.46 Million | -51.17% | 15.15x | $5.85 Million |
| China Shengmu Organic Milk Limited (7OM) | $2.88 Billion | -77.29% | 1.63x | $146.24 Million |
| Måsøval AS (9QP) | $1.79 Billion | -7.59% | 1.88x | $65.29 Million |
| CHA0 (CHA0) | $228.23 Million | -11.57% | 0.15x | $3.54 Million |
| Elders Limited (FTZ) | $1.09 Billion | 4.63% | 1.34x | $869.15 Million |
| Tonkens Agrar AG (GTK) | $5.44 Million | 0.00% | 2.96x | $2.10 Million |
| GDH Guangnan (Holdings) Limited (GUJB) | $2.60 Billion | 4.54% | 0.14x | $30.79 Million |